GURU.Markets stock price, segment price, and overall market index valuation
The company's share price VCYT
Veracyte is a genomic diagnostics company. Its stock price reflects the potential of its tests to improve thyroid and lung cancer diagnostics. The chart tells the story of the commercialization of innovative diagnostic tools and the long road to profitability.
Share prices of companies in the market segment - Cancer analysis
Veracyte is a genomic diagnostics company that offers tests that help doctors make decisions in oncology and other areas. Its key segments are the Afirma thyroid test and the Decipher prostate cancer test. We classify it as part of the Cancer Analysis sector, and the chart below reflects the dynamics of the entire molecular diagnostics industry.
Broad Market Index - GURU.Markets
Veracyte is a genomic diagnostics company that provides tests for early-stage cancer detection. Its innovations make it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Veracyte compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
VCYT - Daily change in the company's share price VCYT
Shares of Veracyte, a company specializing in genomic cancer diagnostics, are highly volatile. Change_co measures market reactions to data on the company's test rollout and insurance company decisions. This metric is an important component of formulas on System.GURU.Markets that evaluate innovative companies in the diagnostics sector.
Daily change in the price of a set of shares in a market segment - Cancer analysis
Veracyte, Inc. is a genomic diagnostics company. This chart highlights the sector's high volatility. Comparing it to VCYT, which focuses on cancer diagnostics, helps assess how sensitive its business is to the introduction of new tests and insurance rates.
Daily change in the price of a broad market stock, index - GURU.Markets
Veracyte is a company specializing in genomic diagnostics for the detection of cancer and other diseases. The oncology diagnostics sector is extremely sensitive to clinical data. The chart below shows the volatility in this niche, reflecting both high expectations and risks.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization VCYT
Veracyte is a leader in genomic diagnostics. Its year-over-year performance reflects rapid growth in testing volumes and investor confidence in the potential of its technologies for early disease detection. The chart below shows the history of this science-intensive business.
Annual dynamics of market capitalization of the market segment - Cancer analysis
Veracyte, Inc. is a genomic diagnostics company developing tests that help doctors make decisions about cancer treatment. Its innovative products target a massive market. The graph shows how its scientific advancements and commercialization efforts are impacting its performance in the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Veracyte, a company specializing in genomic cancer diagnostics, is a growth story in medicine. Its stock price is driven not by the economy, but by demand for its innovative tests that help doctors make accurate diagnoses. The chart reflects how a breakthrough technology can create and capture a new market.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization VCYT
Veracyte, a genomic diagnostics company, depends on the adoption of its tests for its market capitalization. The monthly fluctuations on the chart reflect the growth of testing volumes and, more importantly, insurance reimbursement, which is key to the commercial success of its diagnostic products.
Monthly dynamics of market capitalization of the market segment - Cancer analysis
Veracyte is a genomic diagnostics company offering tests that help doctors make decisions about cancer treatment. Its growth depends on the adoption of these tests in clinical practice and the acquisition of insurance coverage. The dynamics of the biotech sector will reflect the overall investor interest in innovative diagnostics, providing a backdrop for assessing Veracyte's commercial potential.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Veracyte is a genomic diagnostics company whose tests help doctors make decisions about treating cancer and other diseases. Its history is one of growth and innovation. Against the backdrop of market trends shown in the chart, Veracyte's performance is determined by the speed of its tests' adoption and R&D success, rather than macroeconomic factors.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization VCYT
Veracyte, a genomic cancer diagnostics company, is extremely news-sensitive. Weekly price movements reflect research progress, insurance company coverage decisions, and data on increasing usage. The chart below visualizes how short-term developments in the cancer diagnostics world impact the stock.
Weekly dynamics of market capitalization of the market segment - Cancer analysis
How unique is Veracyte's performance in the biotech sector? This chart compares the weekly fluctuations of the genomic diagnostics company's stock to the overall trend. This helps us understand whether its reaction to the test rollout news is unique or follows broader sentiment across the volatile sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Veracyte is a company specializing in genomic cancer diagnostics. Its tests help doctors make more accurate decisions. This chart compares its weekly performance with the market, showing how its stock price is influenced by news about the clinical adoption of its tests and insurance company decisions.
Market capitalization of the company, segment and market as a whole
VCYT - Market capitalization of the company VCYT
Veracyte, Inc.'s market capitalization is a bet on the future of molecular cancer diagnostics. The company develops tests that help doctors make decisions without invasive surgery. Its market capitalization chart shows how investors view the potential of its genomic tests to become the standard in oncology.
VCYT - Share of the company's market capitalization VCYT within the market segment - Cancer analysis
Veracyte, Inc. is a genomic diagnostics company providing tests that help doctors make decisions about treating cancer and other diseases. Its share of its sector market cap reflects the potential of its diagnostic platforms. The chart shows how investors view the acceptance of its tests by the medical community and their impact on treatment outcomes.
Market capitalization of the market segment - Cancer analysis
Here's a chart of the total market capitalization of companies involved in molecular cancer diagnostics. Veracyte is a leader in this field. The graph shows how the market values technologies that enable accurate diagnosis and personalized treatment based on genomic analysis.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart shows the market value of a breakthrough in cancer diagnostics. Veracyte's market capitalization is based on the valuation of its genomic tests, which help doctors make more accurate decisions. The line demonstrates how innovations in testing can create enormous value and become a significant part of the global healthcare economy.
Book value capitalization of the company, segment and market as a whole
VCYT - Book value capitalization of the company VCYT
The book value of Veracyte, Inc., a genomic diagnostics company, is its scientific capital. The chart below reflects the valuation of its laboratories, diagnostic equipment, and, most importantly, patents for unique cancer detection tests. The line's growth reflects investments in expanding its diagnostic solutions portfolio.
VCYT - Share of the company's book capitalization VCYT within the market segment - Cancer analysis
Veracyte's core assets are its advanced laboratories, equipped to conduct complex genomic and diagnostic tests. The chart shows the company's share of this high-tech scientific infrastructure, which is the physical core of its business in early detection of cancer and other diseases.
Market segment balance sheet capitalization - Cancer analysis
Veracyte is a genomic diagnostics company. Its value lies in its unique tests and algorithms, not its manufacturing facilities. Its tangible assets are its state-of-the-art laboratories. The graph will show whether this "lightweight," science-driven model is typical for the entire diagnostics sector.
Book value of all companies included in the broad market index - GURU.Markets
Veracyte's assets include cutting-edge laboratories and unique genomic tests that aid in early-stage cancer diagnosis. Its book value reflects the capital invested in science and technology that has the potential to transform approaches to oncology. The chart illustrates the scale of these diagnostic innovations.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - VCYT
Veracyte is a genomic diagnostics company. Its value lies not in its labs, but in its unique tests that help doctors make decisions in oncology. Its market capitalization reflects the potential of these tests to become standard treatment. The chart shows how investors value the intellectual property and commercial prospects of its diagnostic platforms.
Market to book capitalization ratio in a market segment - Cancer analysis
Veracyte is a genomic diagnostics company offering tests that aid in cancer treatment. Its value lies not in its laboratories, but in its unique technologies and data. The chart clearly demonstrates how much its market valuation, based on the potential of its tests, exceeds its book value.
Market to book capitalization ratio for the market as a whole
Veracyte is a company specializing in genomic cancer diagnostics. The chart shows how the market values this pioneer in personalized medicine. Its market capitalization is based not on the value of its laboratories, but on the value of its unique diagnostic tests, which help doctors make more accurate decisions, creating a high premium to its assets.
Debts of the company, segment and market as a whole
VCYT - Company debts VCYT
Veracyte is a company specializing in genomic diagnostics that helps doctors make decisions about cancer treatment. The company requires significant investment in research and commercialization of its tests. This chart shows how the company is raising capital to expand its testing menu and enter new markets.
Market segment debts - Cancer analysis
Veracyte is a genomic diagnostics company whose tests help doctors make treatment decisions for cancer and other diseases. This is a rapidly growing sector at the intersection of biotechnology and IT. This chart shows the financial norms for an industry where capital is actively raised for research, test validation, and commercial promotion to doctors.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio VCYT
Veracyte is a company specializing in genomic diagnostics that help doctors make decisions about cancer treatment. The development and commercialization of such tests require significant investment. This chart shows how Veracyte finances its research and market entry using equity and debt.
Market segment debt to market segment book capitalization - Cancer analysis
Veracyte is a genomic diagnostics company whose tests help doctors make decisions about treating cancer and other diseases. This chart compares its debt raised for research and acquisitions to the total market capitalization of the entire cancer testing sector. It illustrates the financial implications of implementing advanced diagnostic technologies in medicine.
Debt to book value of all companies in the market
Veracyte, working in the cutting-edge field of genomic diagnostics, requires significant investment. This chart compares its debt to the total book value of the entire economy. It shows how the innovative company's financial needs compare to the overall market conditions, which are the source of capital for its research.
P/E of the company, segment and market as a whole
P/E - VCYT
This chart shows the valuation of Veracyte, Inc., a company in the field of genomic cancer diagnostics. For a company whose value lies in its unique tests, this metric reflects investors' confidence in the widespread adoption of its technologies in clinical practice. It demonstrates how much the market values the potential of its diagnostic tools.
P/E of the market segment - Cancer analysis
This chart shows the average valuation for the molecular diagnostics sector in which Veracyte operates. In this innovative industry, the average valuation can be high, reflecting expectations for future growth. It provides context for understanding how the market values Veracyte's diagnostic platforms compared to other genomics companies.
P/E of the market as a whole
Veracyte is a genomic diagnostics company that provides tests that help doctors make more accurate decisions when diagnosing thyroid and lung cancer, among other diseases. This risk appetite chart helps understand how investors value companies at the forefront of personalized medicine.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company VCYT
Veracyte is a genomic diagnostics company offering tests that help doctors make decisions about treating cancer and other diseases. This chart reflects investor expectations for the widespread adoption of its tests in clinical practice, a bet on the future of personalized medicine.
%20P%2FE%20VCYT&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-VCYT&v=1772476854351 "Chart of the company's future (projected) P/E VCYT")
Future (projected) P/E of the market segment - Cancer analysis
Veracyte is a global genomic diagnostics company. Its tests help doctors answer complex clinical questions in thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis, thereby avoiding unnecessary invasive procedures. This chart shows overall market sentiment in the biotech and diagnostics sectors, helping to assess Veracyte's potential.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-analysis&v=1772476854353 "Future (projected) P/E graph of the market segment - Cancer analysis")
Future (projected) P/E of the market as a whole
Veracyte is a company specializing in genomic cancer diagnostics. Its tests help doctors make more accurate treatment decisions. The company's growth depends on the implementation of its tests in clinical practice and receiving reimbursement from insurance companies. This is a story about how innovation is changing medicine.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772476854354 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit VCYT
Veracyte is a genomic diagnostics company offering tests that help doctors make more accurate treatment decisions for thyroid and lung cancer, among other conditions. Revenue depends on the number of tests performed and their reimbursement by insurance companies. This chart shows how the introduction of innovative diagnostics into clinical practice impacts revenue.
Profit of companies in the market segment - Cancer analysis
Veracyte, Inc. is a genomic diagnostics company offering tests that help doctors make more informed decisions when treating thyroid, lung, and other cancers. This chart shows the profitability of its segment. Its innovative tests are changing approaches to diagnostics, and their adoption in clinical practice is driving growth for the entire niche.
Overall market profit
Veracyte, Inc. is a genomic diagnostics company providing tests that help doctors make decisions about cancer treatment. Demand for its products depends on medical innovation and insurance company acceptance. This chart illustrates general economic cycles, with Veracyte at the forefront of personalized medicine.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company VCYT
Veracyte is a genomic diagnostics company offering tests that help doctors make treatment decisions for cancer and other diseases. This chart reflects analysts' expectations for future profits, which depend on testing volumes and insurance reimbursements. It demonstrates the market's confidence in the potential of personalized medicine.
%20profit%20of%20the%20company%20VCYT&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-VCYT&v=1772476854357 "Graph of future (projected) profit of the company VCYT")
Future (predicted) profit of companies in the market segment - Cancer analysis
Veracyte, Inc. is a genomic diagnostics company offering tests that help doctors make treatment decisions for thyroid, lung, and other cancers. This chart shows revenue forecasts for the cancer testing sector. It reflects expectations for the growth of personalized medicine and the demand for accurate diagnostics.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-analysis&v=1772476854359 "Graph of future (predicted) profits of companies in a market segment - Cancer analysis")
Future (predicted) profit of the market as a whole
Veracyte, Inc. is a genomic diagnostics company offering tests that aid in cancer treatment. The adoption of these advanced tests depends on their inclusion in insurance coverage and clinic budgets. The overall profit forecast reflected here indirectly impacts the health care system. Economic growth ensures stable funding for innovative medicine.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772476854360 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - VCYT
Veracyte, Inc. is a genomic diagnostics company offering tests for early-stage cancer detection. For a growing diagnostics company, P/S is a key metric. It reflects how investors assess the potential of its tests to become a standard in medicine and generate significant revenue.
P/S market segment - Cancer analysis
Veracyte, Inc. is a genomic diagnostics company that provides tests that help doctors make treatment decisions for thyroid and lung cancers, among other conditions. Their revenue is growing as their tests are deployed. The chart below shows how the market views their innovative diagnostic platforms and their potential to transform the standard of care.
P/S of the market as a whole
Veracyte is a genomic diagnostics company that helps doctors make decisions about cancer treatment. Revenue is growing as its tests are adopted into clinical practice. This chart illustrates the average revenue estimate, which helps understand the market premium placed on this company for innovation and growth potential in personalized medicine.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company VCYT
Veracyte is a genomic diagnostics company developing tests to help doctors make decisions about treating cancer and other diseases. This chart reflects investor expectations for future revenue from increased testing volume as its innovative diagnostic tests become more widely used in clinical practice.
%20P%2FS%20VCYT&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-VCYT&v=1772476854364 "The graph of the company's future (projected) P/S VCYT")
Future (projected) P/S of the market segment - Cancer analysis
Veracyte, Inc. is a genomic diagnostics company offering tests that help doctors make more accurate decisions in cancer diagnosis and treatment. This chart shows how the market estimates future revenue from its innovative tests compared to other companies in the cancer testing sector. It reflects the belief in the potential of genomics to improve cancer care.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-analysis&v=1772476854365 "Future (projected) P/S market segment graph - Cancer analysis")
Future (projected) P/S of the market as a whole
Veracyte is a genomic diagnostics company. Its tests help doctors make more accurate diagnoses for cancer and other diseases, avoiding invasive procedures. This chart shows aggregate market expectations for future revenue, and Veracyte demonstrates how personalized medicine and advanced diagnostics are becoming important growth drivers in healthcare.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772476854365 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales VCYT
Veracyte, Inc. is a genomic diagnostics company that provides tests that help doctors make more accurate decisions in cancer diagnosis and treatment. The chart shows revenue from these tests. Sales growth depends on the expansion of the test portfolio, their acceptance by the medical community, and reimbursement from insurance companies.
Sales of companies in the market segment - Cancer analysis
Veracyte is a company specializing in genomic cancer diagnostics. This chart segments its revenue by key diagnostic tests, such as Afirma (thyroid cancer) or Decipher (prostate cancer). This allows investors to assess the commercial success of each product and its acceptance by the medical community.
Overall market sales
Veracyte, Inc. is a genomic diagnostics company that helps doctors make decisions about cancer treatment. Demand for its tests is driven by the pursuit of personalized medicine. This long-term trend makes Veracyte less dependent on short-term economic cycles, as this chart illustrates. The primary driver is the clinical value of its tests.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company VCYT
Veracyte is a genomic diagnostics company offering tests that help doctors make decisions about treating cancer and other diseases. Its revenue forecast depends on the number of tests performed and their reimbursement by insurance companies. This chart shows how analysts estimate the adoption of its tests in clinical practice.
%20sales%20of%20the%20company%20VCYT&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-VCYT&v=1772476854371 "Schedule of future (projected) sales of the company VCYT")
Future (projected) sales of companies in the market segment - Cancer analysis
Veracyte is a company specializing in genomic cancer diagnostics. This chart displays projected revenues for the entire oncology testing segment. It provides an estimate of how rapidly analysts expect the molecular diagnostics market to grow, which is critical for the clinical adoption of Veracyte's tests and their commercial success.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-analysis&v=1772476854371 "Schedule of future (projected) sales of companies in the market segment - Cancer analysis")
Future (projected) sales of the market as a whole
Veracyte is a genomic diagnostics company that helps doctors make decisions about cancer treatment. Demand for its tests depends on the implementation of innovations in oncology. The overall economic situation, reflected in the graph, affects the budgets of healthcare systems and insurance companies, which determine coverage and reimbursement for Veracyte's advanced diagnostic tests.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772476854372 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality VCYT
Veracyte is a genomic diagnostics company that provides tests to help doctors make decisions about cancer treatment. This graph shows the path to profitability in the field of personalized medicine. Profitability depends on the number of tests performed and the level of reimbursement from insurance companies.
Market segment marginality - Cancer analysis
Veracyte is a genomic diagnostics company whose tests help doctors make treatment decisions for thyroid cancer, lung cancer, and other diseases. This indicator reflects the value of its diagnostic tests. High profitability speaks to the clinical benefit of its products and their integration into standard medical care.
Market marginality as a whole
Veracyte, Inc. is a genomic diagnostics company offering tests that help doctors make decisions about treating cancer and other diseases. This chart shows average profitability, while Veracyte is at the forefront of personalized medicine, where innovations can radically change approaches to diagnosis and treatment.
Employees in the company, segment and market as a whole
Number of employees in the company VCYT
Veracyte is a genomic diagnostics company that provides tests to help doctors make decisions about cancer treatment. Its staff consists of scientists, laboratory technicians, and sales specialists. The growth in this chart reflects the increase in the number of tests performed and the expansion of its diagnostic product portfolio.
Share of the company's employees VCYT within the market segment - Cancer analysis
Veracyte, Inc. is a genomic diagnostics company offering tests that help doctors make decisions about cancer treatment. This chart highlights its innovative contributions to medicine. It reflects the proportion of molecular biologists, bioinformaticians, and pathologists working at the forefront of genomic diagnostics that Veracyte brings together.
Number of employees in the market segment - Cancer analysis
Veracyte, Inc. is a genomic diagnostics company offering tests that help doctors make more accurate cancer treatment decisions. This chart shows employment in the cancer testing sector. The growth in this cutting-edge field reflects the revolution in personalized medicine and the growing demand for diagnostic tools.
Number of employees in the market as a whole
Veracyte is a company focused on genomic cancer diagnostics. The growth of its team of scientists and lab technicians reflects the revolution in personalized medicine. It's an example of how cutting-edge scientific research is creating a new industry that not only saves lives through early detection but also creates the healthcare jobs of the future.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company VCYT (VCYT)
Veracyte is a company specializing in genomic cancer diagnostics. Their tests help doctors make more accurate decisions. Their value lies in their unique algorithms and scientific data. This chart shows that the market highly values their intellectual capital. Value is created not by mass production, but by cutting-edge science, which is what drives their high valuation.
%20of%20the%20company%20VCYT%20(VCYT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-VCYT-VCYT&v=1772476854384 "Chart of market capitalization per employee (in thousands of dollars) of the company VCYT (VCYT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer analysis
Veracyte is a molecular diagnostics company. They develop tests (for example, for lung or thyroid cancer) that help avoid unnecessary surgeries. Their value lies in their R&D and data. This chart shows the industry average, helping to estimate the market value generated by this innovative diagnostic platform.
%20by%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-analysis&v=1772476854387 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer analysis")
Market capitalization per employee (in thousands of dollars) for the overall market
Veracyte is a genomic diagnostics company developing tests that help doctors make decisions about treating cancer and other diseases. Its value lies in its science and data. This chart reflects the high praise it receives from every scientist and bioinformatician whose work enables the creation of innovative diagnostic tools.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772476854389 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company VCYT (VCYT)
Veracyte is a genomic diagnostics company. It develops tests that help doctors make decisions about thyroid, lung, and other cancers, avoiding invasive procedures. This chart shows how successfully the company is selling these high-tech, expensive tests and whether revenue covers its high R&D costs.
%20Chart%20VCYT%20(VCYT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-VCYT-VCYT&v=1772476854390 "Company Profit Per Employee (in thousands of dollars) Chart VCYT (VCYT)")
Profit per employee (in thousands of dollars) in the market segment - Cancer analysis
Veracyte is a "diagnostic" company. They offer "genomic" tests that aid in cancer diagnosis (thyroid, lung). This graph shows the benchmark for "Med-Analytics." In this R&D sector, the benchmark is high. Revenue per employee (scientist) is generated by "patents" for tests, which are sold at high margins.
%20in%20the%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-analysis&v=1772476854392 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer analysis")
Profit per employee (in thousands of dollars) for the market as a whole
Veracyte is a genomic diagnostics company. They develop tests (such as Afirma for thyroid cancer) that help doctors make cancer treatment decisions. This is MedTech R&D. This metric, which illustrates the average profitability per employee in the economy, helps us understand how efficient a genomic diagnostics sector like Veracyte is.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772476854392 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee VCYT (VCYT)
Veracyte, Inc., a genomic diagnostics company, shows the commercialization process of its tests in this chart. The growth in revenue per employee reflects the increase in the number of tests performed and reimbursement from insurance companies, demonstrating recognition of the clinical value of its diagnostic products.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-VCYT-VCYT&v=1772476854394 "Sales chart per company employee VCYT (VCYT)")
Sales per employee in the market segment - Cancer analysis
Veracyte is a genomic diagnostics company offering cancer detection tests (such as thyroid cancer). It's a high-tech healthcare company. This chart shows the average revenue per employee in the segment. It helps evaluate how productive Veracyte's team (R&D, lab technicians) is in developing and selling its diagnostic tests.
Sales per employee for the market as a whole
Veracyte (VCYT) is a genomic diagnostics company. They offer tests (for example, for thyroid cancer) that help avoid unnecessary surgeries. It's a high-tech business. This metric reflects the demand for their tests. Their growth suggests that more and more doctors are using their diagnostics, monetizing their R&D.
Short shares by company, segment and market as a whole
Shares shorted by company VCYT (VCYT)
Veracyte specializes in genomic diagnostics, offering tests that help doctors make decisions in oncology (for example, thyroid or lung cancer). This chart shows concerns about their tests. "Bearers" may be betting that insurance companies will not reimburse these expensive tests or that competitors will offer more accurate tests.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-VCYT-VCYT&v=1772476854397 "Short Shares Chart for the Company VCYT (VCYT)")
Shares shorted by market segment - Cancer analysis
Veracyte is a genomic diagnostics company. Its tests help doctors make decisions about thyroid and lung cancer, avoiding unnecessary surgeries. This chart shows pessimism in the sector. The increase in short positions in the industry may indicate that investors are concerned about changes in the Medicare reimbursement system, which could reduce the profitability of such tests.
Shares shorted by the overall market
Veracyte (VCYT) is a genomic diagnostics company offering tests that help doctors make decisions when diagnosing cancer (such as thyroid or lung cancer). This chart highlights the overall market pessimism. Rising fears mean investors are fleeing risky biotechs. For VCYT, this is a test: do investors view it as a speculative growth story or a mature company with important diagnostic products?
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator VCYT (VCYT)
Veracyte specializes in genomic diagnostics (thyroid and lung cancer). Its business depends on test adoption and insurance reimbursement. A chart above 70 may reflect positive reimbursement news or an increase in testing volume. A range below 30 indicates slow adoption or payment issues.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-VCYT-VCYT&v=1772476854402 "RSI 14 indicator chart for the company's stock VCYT (VCYT)")
RSI 14 Market Segment - Cancer analysis
Veracyte is a genomic diagnostics company. Its tests (such as Afirma for thyroid and Percepta for lungs) help doctors make decisions in oncology and pulmonology. This chart shows the overall sentiment in the molecular diagnostics sector. It helps us understand whether the VCYT trend is part of a general "overheating" in genomics or a result of the introduction of its tests.
RSI 14 for the overall market
Veracyte (VCYT) is developing genomic tests for cancer diagnostics. This chart reflects insurance companies' willingness to pay for expensive innovations. During periods of euphoria and budget growth, they more readily approve new tests. During times of panic and cost savings, insurers may tighten requirements, preferring older, cheaper diagnostic methods.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast VCYT (VCYT)
Veracyte (VCYT) is a genomic diagnostics company developing tests that help doctors make decisions about thyroid cancer, lung cancer, and interstitial lung disease. The chart shows the average Wall Street forecast, reflecting analyst expectations for testing volumes and insurance reimbursement for these tests.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-VCYT-VCYT&v=1772476854407 "A chart showing analyst consensus forecasts for the expected stock price. VCYT (VCYT)")
The difference between the consensus estimate and the actual stock price VCYT (VCYT)
Veracyte is a genomic diagnostics company. Their tests (Afirma, Decipher) help doctors make accurate diagnoses for suspected thyroid or prostate cancer. This chart shows the gap between the current market valuation and the analyst target price. It highlights the potential experts see in their diagnostic platforms.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-VCYT-VCYT&v=1772476854408 "A chart showing the difference between the consensus forecast and the actual stock price. VCYT (VCYT)")
Analyst consensus forecast for stock prices by market segment - Cancer analysis
Veracyte is a genomic diagnostics company. It develops tests that analyze genes in a sample (for example, thyroid) to determine whether a tumor is cancerous. This chart shows general expectations for the cancer testing sector, reflecting experts' confidence in the future of molecular diagnostics.
Analysts' consensus forecast for the overall market share price
Veracyte (VCYT) is a genomic diagnostics company. Their tests (Afirma, Decipher) help clarify cancer diagnoses (thyroid, prostate), avoiding unnecessary surgeries. This schedule, reflecting expert expectations, influences them. In a recession (pessimism), insurers (payers) are reluctant to approve new, expensive, albeit cost-saving tests.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index VCYT
Veracyte is a molecular diagnostics company. Their tests (such as Afirma for thyroid) analyze genomic markers to help doctors avoid unnecessary surgeries. This graph is an indicator of the acceptance of their tests. It likely aggregates the number of tests performed and their success in obtaining reimbursement from insurance companies.
AKIMA Market Segment Index - Cancer analysis
Veracyte (VCYT) is an innovator in genomic diagnostics; the company produces advanced molecular tests that help doctors make accurate diagnoses (thyroid and lung cancer). This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does VCYT's high-tech diagnostic model differentiate it from the average pharmaceutical company?
The AKIM Index for the overall market
Veracyte is a genomic diagnostician. The company develops advanced molecular tests that help doctors diagnose cancer (thyroid, lung). This chart, reflecting the market average, is a backdrop. It helps assess how this growth story in the defensive healthcare sector compares to overall macroeconomic trends.
